Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis Jettisons Key Evidence from Diovan Promotion
February 6, 2013
- Sales and Profits Jump for Shionogi in April-December with US Sales Recovery
February 6, 2013
- Latuda Serves as Driving Force for Growth in North American Market: DSP President Tada
February 6, 2013
- Takeda Lowers Full-Year Sales Forecast for Nesina, but Says Nesina Remains “Fastest-Growing DPP-4 Inhibitor”
February 6, 2013
- Sales in Emerging Markets Contribute to Growth in Sales for April-December Despite Fall in Sales of All 4 Major Products: Takeda
February 6, 2013
- Daiichi Sankyo Starts PIII Trial of ARQ 197 in HCC Patients
February 5, 2013
- DSP Posts 46.5 % Rise in April-December Operating Profit Despite Japan Sales Fall
February 5, 2013
- Nesp, Mircera Jostling for Market Shares of Pre-Dialysis CKD Patients
February 5, 2013
- Teijin Pharma Appoints Hiroshi Uno as New President Effective from April 1
February 5, 2013
- 13.9 Bil. in Royalties from Gilenya Help Boost Consolidated Sales for April-December: MTPC
February 5, 2013
- Kyowa Kirin Posts Record Operating Profit for 2012; Sales Up 9% in Pharma Division
February 5, 2013
- Eisai’s Operating Profit Drops 34% in April-December as Aricept Sales Fall
February 4, 2013
- Aricept Fails to Meet Minimum Sales Target in Japan: Eisai
February 4, 2013
- Astellas April-Dec. Earnings: XTANDI Starts Off on Good Note, Could Outstrip Full-Year Target
February 4, 2013
- Kyowa Kirin to Launch 3 In-House Products in Europe and US, Aims for Sales of 358 Billion Yen in 2015: New Midterm Plan
February 4, 2013
- Marketing Ability Could Become Decisive Factor as All DPP-4 Inhibitors Are Likely to Obtain the Same Concurrent-use Indications
February 4, 2013
- Daiichi Sankyo Sees 7.1% Sales Rise in April-December, Cuts Domestic Forecast for Nexium
February 1, 2013
- Chugai Begins Development of Hyperlipidemia Antibody RG7652
February 1, 2013
- Oncology Products Boost Sales, Profits in 2012, but Both Fall Short of Midterm Targets: Chugai
February 1, 2013
- Chugai’s New Midterm Plan Includes No Sales or Profit Targets, Aims for Increased Marketing Productivity
February 1, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…